Sep 30, 2022

Penumbra Q3 2022 Earnings Report

Reported financial results for the third quarter ended September 30, 2022.

Key Takeaways

Penumbra, Inc. reported a 12.4% increase in revenue, reaching $213.7 million in the third quarter of 2022 compared to the third quarter of 2021.

Total revenue increased to $213.7 million, a 12.4% increase compared to Q3 2021.

Revenue from vascular products grew 17.0% to $123.4 million.

Revenue from neuro products grew 6.7% to $90.3 million.

The company is updating its 2022 revenue guidance to account for two, near-term dynamics: the Lightning Flash product launch is now expected to occur in the first quarter of 2023, six weeks later than the previous mid-fourth quarter 2022 estimate, and an incremental headwind of $4-6 million from foreign currency translations.

Total Revenue
$214M
Previous year: $190M
+12.4%
EPS
$0.01
Previous year: $0.12
-91.7%
Gross Margin
63.3%
Previous year: 63.1%
+0.3%
Gross Profit
$135M
Previous year: $120M
+12.9%
Cash and Equivalents
$54.8M
Previous year: $66.3M
-17.3%
Free Cash Flow
-$19.3M
Previous year: $30.6M
-162.8%
Total Assets
$1.32B
Previous year: $973M
+35.8%

Penumbra

Penumbra

Penumbra Revenue by Segment

Penumbra Revenue by Geographic Location

Forward Guidance

The Company now expects 2022 total revenue to be in the range of $840 million to $845 million, which reflects growth of 12-13% on a reported basis and 15-16% in constant currency compared to 2021. Looking forward to 2023, the Company expects to achieve the $1 billion level in total revenue.

Challenges Ahead

  • The Lightning Flash product launch is now expected to occur in the first quarter of 2023, six weeks later than the previous mid-fourth quarter 2022 estimate
  • An incremental headwind of $4-6 million from foreign currency translations.

Revenue & Expenses

Visualization of income flow from segment revenue to net income